EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA / EMA

Takahiro Handa iD, Arata Tanaka iD, Mayumi Shikano iD, Rika Wakao iD

Clinical and Translational Science · 2026-06 · 19 (6)

DOI: 10.1111/cts.70642 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Translational Science, online erschienen am 18.06.2026. Verfasst von Takahiro Handa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Expedited pathways in the United States (U.S.), European Union (EU), and Japan (JP) enable earlier access to innovative therapies for rare and serious diseases. In 2025, Japan explicitly introduced revocation provisions to its Conditional Early Approval (CEA). Considering the challenges in a related prior scheme—conditional and time‐limited approval for regenerative medical products—particularly withdrawals prior to full approval, this study examined oncology cases under the U.S. Accelerated Approval (AA) and EU Conditional Marketing Authorization (CMA) pathways to identify operational challenges for revocation under Japan's CEA. We conducted a descriptive comparative analysis of oncology drugs granted AA or CMA between January 2015 and December 2024 using publicly available data. Post‐authorization outcomes and JP approval/development status were summarized. AA encompassed 97 products (138 indications), CMA included 27 products (30 indications), and CEA covered 4 products (4 indications). Approximately half of AA/CMA indications were approved in Japan, while some remained undeveloped. The mean time from AA to full approval was 2.7 years and to withdrawal was 3.6 years. Overall, about 15% of AA indications were withdrawn, primarily due to failed confirmatory trials; 8 products/10 indications underwent Oncologic Drugs Advisory Committee deliberations prior to withdrawal or continuation. With recent policy changes aligning CEA eligibility with AA/CMA, broader implementation of CEA is anticipated. For revocation operations, three priorities emerge: (1) timely confirmatory trials and alternative approaches to reduce uncertainty; (2) transparent public evaluation and decision‐making; and (3) flexible patient‐access systems following withdrawal. Continued discussion is required to support effective use of CEA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsJapanUnited StatesHumansUnited States Food and Drug AdministrationEuropean Union

Stichwörter der Autor:innen

FDAdrug developmentoncologypatientspublic policyregulatory

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
  • Late Development Oncology TA Division, AstraZeneca K.K., Tokyo, Japan.
  • Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.

ORCID-Profile: Takahiro Handa, Arata Tanaka, Mayumi Shikano, Rika Wakao

Zitieren

APA

Handa, T., Tanaka, A., Shikano, M., & Wakao, R. (2026). Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA / EMA. Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70642

Vancouver

Handa T, Tanaka A, Shikano M, Wakao R. Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA / EMA. Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70642

BibTeX
@article{Handa2026,
  author = {Handa, Takahiro and Tanaka, Arata and Shikano, Mayumi and Wakao, Rika},
  title = {Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA / EMA},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {6},
  doi = {10.1111/cts.70642}
}
Kostenlos starten →